Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment

Other users also viewed these articles

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab Luis Figuero-Pérez, Alejandro Olivares-Hernández, Roberto A. Escala-Cornejo, Eduardo Terán-Brage, Álvaro López-Gutiérrez, Juan J. Cruz-Hernández

10.1016/j.reumae.2020.06.008

Use of anakinra in the treatment of SARS-CoV-2 severe respiratory infection Luis Figuero-Pérez, Alejandro Olivares-Hernández, Roberto A. Escala-Cornejo, Juan J. Cruz-Hernández

10.1016/j.reumae.2022.02.001

Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19 Alejandro Muñoz-Jiménez, Esteban Rubio-Romero, José Luis Marenco de la Fuente

10.1016/j.reumae.2020.04.012